Recent Development in Obesity Pharmacogenomics

(2000-2005)

à Pharmacogenetics of antipsychotic-induced weight gain.

Correll CU, Malhotra AK.
Psychopharmacology. 2004 Aug;174(4):477-89.

à Serotonin transporter: gene, genetic disorders, and pharmacogenetics.

Murphy DL, Lerner A, Rudnick G, Lesch KP.
Mol Interv. 2004 Apr;4(2):109-23.
à Pharmacogenetics of antipsychotic-induced weight gain.

Muller DJ, Muglia P, Fortune T, Kennedy JL.
Pharmacol Res. 2004 Apr;49(4):309-29.

à Pharmacogenetics of soluble sulfotransferases (SULTs).

Glatt H, Meinl W.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):55-68.

à PPARs: molecular targets in the pharmacogenomics era.

Seda O, Sedova L.
Prague Med Rep. 2004;105(3):223-36.  

à High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study.

Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, Wietlisbach V, Riesen WF, Walther T, Medinger L, Nicod P, Desvergne B, Mooser V.
Ann Intern Med. 2002 Apr 16;136(8):582-9.

à Genetics of obesity.

Clement K, Boutin P, Froguel P.
Am J Pharmacogenomics. 2002;2(3):177-87.  

à Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders.

Adan RA, Vink T.
Eur Neuropsychopharmacol. 2001 Dec;11(6):483-90.

à Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.

Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL.
J Clin Psychiatry. 2001;62 Suppl 23:45-66.

à Human genomics and obesity: finding appropriate drug targets.

Ravussin E, Bouchard C.
Eur J Pharmacol. 2000 Dec 27;410(2-3):131-145.